AC Immune (ACIU)
(Delayed Data from NSDQ)
$3.91 USD
0.00 (0.00%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $3.90 -0.01 (-0.26%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACIU 3.91 0.00(0.00%)
Will ACIU be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ACIU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACIU
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
ACIU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
Other News for ACIU
AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward
AC Immune stock climbs 7% on FDA fast track status for Alzheimer's drug
AC Immune's ACI-35.030 granted FDA Fast Track Designation
AC Immune?s ACI-35.030 (now ?JNJ-2056?) Granted FDA Fast Track Designation for Alzheimer?s Disease
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024